Radpharm Management Limited - Accounts to registrar (filleted) - small 18.2

REGISTERED NUMBER: 06508826 (England and Wales)

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2020

FOR

RADPHARM MANAGEMENT LIMITED

Page

Company Information

1

Statement of Financial Position

2

Notes to the Financial Statements

4

DIRECTORS:

Mrs S Radia

Mr S C Radia

REGISTERED OFFICE:

Unit 2.02

High Weald House

Glovers End

Bexhill

East Sussex

TN39 5ES

REGISTERED NUMBER:

06508826 (England and Wales)

ACCOUNTANTS:

Acuity Professional Partnership LLP

Unit 2.02

High Weald House

Glovers End

Bexhill

East Sussex

TN39 5ES

FIXED ASSETS

Investments

4

2,383,416

2,348,214

CURRENT ASSETS

Debtors

5

1,131,001

906,163

Cash at bank

24,078

19,212

1,155,079

925,375

CREDITORS

Amounts falling due within one year

6

1,653,515

1,538,677

NET CURRENT LIABILITIES

(498,436

)

(613,302

)

TOTAL ASSETS LESS CURRENT LIABILITIES

1,884,980

1,734,912

CAPITAL AND RESERVES

Called up share capital

7

100

100

Retained earnings

1,884,880

1,734,812

SHAREHOLDERS' FUNDS

1,884,980

1,734,912

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2020.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2020 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 24 September 2021 and were signed on its behalf by:

Mr S C Radia - Director

1.	STATUTORY INFORMATION

Radpharm Management Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

BASIS OF PREPARING THE FINANCIAL STATEMENTS

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

TURNOVER

Revenue is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

INVESTMENTS IN SUBSIDIARIES

Investments in subsidiary undertakings are recognised at cost.

TAXATION

Taxation for the year comprises of current tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2019 - 2 ) .

4.	FIXED ASSET INVESTMENTS

Shares in

group

Listed

undertakings

investments

Totals

£

£

£

Cost or valuation

At 1 January 2020

1,326,374

1,021,840

2,348,214

Additions

-

299,135

299,135

Disposals

-

(304,414

)

(304,414

)

Revaluations

-

40,481

40,481

At 31 December 2020

1,326,374

1,057,042

2,383,416

Net book value

At 31 December 2020

1,326,374

1,057,042

2,383,416

At 31 December 2019

1,326,374

1,021,840

2,348,214

Cost or valuation at 31 December 2020 is represented by:

Shares in

group

Listed

undertakings

investments

Totals

£

£

£

Valuation in 2019

1,326,374

1,057,042

2,383,416

5.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2020

2019

£

£

Amounts owed by group undertakings

158,101

158,101

Other debtors

797,244

722,244

Directors' current accounts

146,425

-

VAT

29,231

25,818

1,131,001

906,163

6.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2020

2019

£

£

Amounts owed to group undertakings

1,621,147

1,486,318

Tax

27,868

47,561

Directors' current accounts

-

397

Accruals and deferred income

4,500

4,401

1,653,515

1,538,677

7.	CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:

Class:

Nominal

2020

2019

value:

£

£

100

Ordinary

£1

100

100

8.	RELATED PARTY DISCLOSURES

During the year, total dividends of £11,750 (2018: £12,000) were paid to the directors.

At the year end, an amount of £1,621,147 (2019: £1,486,318) was owed to Radpharm Ltd, a wholly owned subsidiary of Radpharm Management Ltd.

9.	ULTIMATE CONTROLLING PARTY

The company is under the joint control of Mr and Mrs S Radia, its directors, by virtue of their shareholding.